Pharmaceutical Executive
November 01, 2011
Issue PDF
0
0
Red Light on the Access Autobahn
November 01, 2011
Features
0
0
Will the structure and ambiguity of Germany's new medicines pricing system bring a halt to new drug launches in Europe's largest market?
November 01, 2011
0
0
We ask three managers building Greenfield plants to rationalize and defend their decisions
November 01, 2011
0
0
How is the world's dedicated pharma leader going to improve its positioning in Russia? Pfizer's country manager Christian Holmer comments.
November 01, 2011
0
0
Five years of legislation in the Russian pharmaceutical industry
November 01, 2011
Column
0
0
With OTCs challenging traditional approaches to quality, new opportunities are arising to support industry innovation and advance public health.
November 01, 2011
Column
0
0
The EC's latest proposals have thrown water on Europe's firey Direct-to-Consumer advertising debate. But is it enough to keep the flames at bay?
November 01, 2011
Column
0
0
Clamor for critical therapies prompts probes of prices, production practices.
November 01, 2011
Column
0
0
The bigger the company, the thicker the sclerosis, the more they need to suck out the fat
November 01, 2011
Column
0
0
Industry critics point to a lag in NME approvals as proof of innovation stagnation, but combination products and new delivery systems are quietly saving lives, and bringing in big dollars.
November 01, 2011
0
0
Russia had been a country in flux-monetary crises, corruption scandals, oil surpluses, etc. But no multinational should be scared off by the market anymore, not with its economy on the verge of breaking out.
November 01, 2011
From the Editor
0
0
If high prices that lower access are attributable to a flawed R&D model, can industry embrace delivering better results at lower costs.
November 01, 2011
Back Page
0
0
Pharm Exec's 2011 Emerging Leaders celebration convened Oct. 6 in New York.
November 01, 2011
Features
0
0
Over 25 years the Rx Club Show has reflected dramatic technological changes in advertising. But, as always, the subject comes first, the medium second. So where did the accolades go this year?